Which weight-related comorbidities qualify you for Wegovy in the UK

Step 1, Knowing which conditions count as a weight-related comorbidity for Wegovy

The Wegovy SmPC, which governs how licensed prescribers in the UK use the medicine, lists the weight-related conditions that can bring the qualifying BMI threshold down from 30 to 27. These include type 2 diabetes, prediabetes, hypertension (high blood pressure), dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and cardiovascular disease. Osteoarthritis of the weight-bearing joints is another condition often discussed at consultation, as mechanical load on knees and hips is directly influenced by body weight.

The key word is weight-related: the condition should be one where sustained weight loss would be expected to produce a clinically meaningful improvement. That is a clinical judgement, not a tick-box exercise. A prescriber looks at the severity of each condition, how well it is currently managed, and whether your overall health picture makes semaglutide appropriate. You can read a broader overview of how individual comorbidities interact with Wegovy if you want to understand the detail before your consultation.

It is also worth knowing that for some South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean backgrounds, UK guidance applies the 2.5 kg/m² reduction to thresholds consistently, so the effective minimum BMI with a comorbidity can be as low as 24.5. NICE's appraisal of semaglutide for weight management (TA875) sets out the underpinning rationale for these adjusted thresholds in detail.

Step 2 (Documenting the comorbidity before your consultation

Online consultations for Wegovy ask you about your current diagnoses, prescribed medicines, and any monitoring results you have to hand) for instance, a recent blood pressure reading, a HbA1c result, or a record of a sleep study. You do not need a letter from your GP, but having that information ready helps the prescriber assess your case accurately on the same day.

Transfer patients (people already on semaglutide or tirzepatide elsewhere and moving their care to a new provider) are asked for evidence of their current dose and recent clinical review. This is standard good practice, not an obstacle. If a condition like hypertension has recently been diagnosed, a prescription record or a blood pressure log from a pharmacy monitor is generally sufficient evidence for the prescriber to work with.

The consultation is also the moment to mention medicines that interact with Wegovy. Women taking oral contraceptives alongside tirzepatide face a specific consideration, but for semaglutide the NHS notes no equivalent evidence of reduced pill absorption, nonetheless, discuss any regular medication openly. You can read about how Wegovy fits alongside other weight management medicines if you are currently taking something else.

Step 3 (What happens when the prescriber reviews your comorbidity profile

A GPhC-registered Independent Prescriber reads your full consultation) answers, uploaded evidence and declared medical history. They are making a clinical decision, not running a checklist. For someone with a BMI of 28 and well-controlled type 2 diabetes, for example, the prescriber considers whether semaglutide is likely to benefit overall health and whether there are any contraindications that would rule it out, such as a personal or family history of medullary thyroid carcinoma or a history of pancreatitis.

If approved, treatment with Wegovy starts at 0.25mg and is titrated by the prescriber across several months. The pen sits neatly in the fridge door and is taken once a week on whatever day suits you. Subsequent clinical reviews (required before each repeat is dispensed) give the prescriber the opportunity to reassess the comorbidity picture: has blood pressure improved? Has the sleep apnoea become less severe? These changes inform ongoing care.

Side effects are most commonly gastrointestinal. Nausea, loose stools, and reflux are the ones patients raise most often, particularly in the early weeks. The NHS medicines page for semaglutide lists these in full and explains what to watch for. If you experience severe, persistent stomach pain that radiates to the back, seek medical attention promptly, this can be a sign of pancreatitis, an infrequent but serious reaction flagged in MHRA safety guidance. Our guide to digestive side effects on Wegovy covers the more common and manageable end of that spectrum.

Step 4, NHS eligibility versus private treatment for those with comorbidities

NICE's recommendation for Wegovy (TA875) on the NHS requires the medicine to be used within a specialist weight management service for a maximum of two years, with multidisciplinary support, and applies to adults with a BMI of 35 or above (or 32.5 for eligible ethnic backgrounds) plus at least one weight-related condition. Waiting lists for those services are commonly long, and not every area has the same provision.

Private treatment through a regulated UK online pharmacy is a separate route, available for people who meet the licensed criteria (BMI 30 or above, or 27 with a comorbidity) without needing a referral or meeting the higher NICE NHS thresholds. There is no cap on treatment duration in the private licensed indication, and reviews happen before every repeat is dispensed. If you are weighing up those options, the relationship between starting weight and Wegovy treatment gives useful context, and the evidence on how much weight Wegovy typically reduces is worth reading before you decide.

Cost is a reasonable question at this point. Private Wegovy pricing varies by dose and provider; our treatment page shows current pricing clearly, with no hidden fees. We do not run discount codes or promotional offers for prescription medicines, and if you see a site that does, that is a reason for caution. One transparent price covers consultation, prescription, and free next-working-day delivery. You can explore how pricing works more broadly on our weight loss treatment overview.

If you have a weight-related condition and want to understand whether Wegovy is right for your situation, speaking to our prescribers is the straightforward next step. Speak to our prescribers through a free consultation, reviewed the same day, with no waiting list.